Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 1;215(5):818-823.
doi: 10.1093/infdis/jiw629.

Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein

Affiliations

Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein

Sinthujan Jegaskanda et al. J Infect Dis. .

Abstract

Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against avian influenza virus subtypes, including H7N9 and H5N1, have been detected in human sera. Using NK cell activation and NK cytotoxicity assays, we compared ADCC-mediating antibodies (ADCC-Abs) in sera collected from healthy infants, children and adults against H7N9 virus-infected cells and recombinant hemagglutinin (HA), neuraminidase (NA), and nucleoprotein (NP) proteins. High titers of ADCC-Abs against H7N9 virus-infected cells were detected in sera from adults and children but not infants. ADCC-Abs titers directed against H7N9 HA or NA proteins. Further analysis showed that ADCC-Abs titers were significantly higher toward H7N9 NP, as compared with H7N9 HA or NA proteins, and correlated strongly with ADCC-Abs titers against H7N9 virus-infected cells. Indeed, ADCC-Abs to NPs of seasonal H1N1 and H3N2 viruses correlated strongly with ADCC-Abs to H7N9 NP, suggesting that seasonal influenza infections and vaccinations may induce these cross-reactive antibodies. Targeting ADCC-Abs to internal proteins may be a potential mechanism of universal vaccine design.

Keywords: ADCC; antibody; antibody-dependent cellular cytotoxicity; influenza virus; nucleoprotein.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antibody-dependent cellular cytotoxicity–mediating antibodies (ADCC-Abs) that recognize A(H7N9) virus–infected cells in sera of healthy subjects do not directly target H7N9 hemagglutinin (HA) or neuraminidase (NA) proteins. ADCC-Ab titers were measured against A/Anhui/01/2013 H7N9 virus–infected A549 cells (A), A/Anhui/01/2013 rHA protein (B), or A/Anhui/01/2013 rNA protein (C) in sera from infants (n = 10), children (n = 52), and adults (n = 16). Bars indicate median titers. Titers were compared using separate Mann–Whitney U tests (**P < .05; ns = not statistically significant).
Figure 2.
Figure 2.
H7N9-specific antibody-dependent cellular cytotoxicity–mediating antibodies (ADCC-Abs) are generated toward the H7N9 nucleoprotein. ADCC-Ab titers against recombinant A/Anhui/01/2013 (H7N9) nucleoprotein (NP) in sera from infants (n = 10), children (n = 52), and adults (n = 16) (A). Linear correlation analysis of ADCC-Ab titers against H7N9 NP and H7N9 virus-infected cells measured by NK cell activation assay (B) or cytotoxicity assay (cytotoxicity assay results have been published elsewhere [14]) (C). Bars indicate median titers. Titers were compared using separate Mann–Whitney U tests (**P < .05; ns = not statistically significant). In (B) and (C) some dots represent >2 samples.
Figure 3.
Figure 3.
Antibody-dependent cellular cytotoxicity–mediating antibodies (ADCC-Abs) to H7N9 nucleoprotein (NP) correlate strongly with ADCC-Abs to seasonal influenza NP. ADCC-Ab titer against recombinant NP from A/Puerto Rico/8/1934 (H1N1), A/California/07/2009 (H1N1pdm09), or A/Hong Kong/1/1968 (H3N2) in sera from infants (I, n = 10), children (C, n = 52), and adults (A, n = 16) (A). Linear correlation analysis of H7N9 NP ADCC-Ab titers versus titers to NPs of A/Puerto Rico/8/1934 (H1N1, B), A/California/07/2009 (H1N1pdm09, C), or A/Hong Kong/1/1968 (H3N2, D). Bars indicate median titers. Titers were compared using separate Mann–Whitney U tests (**P < .05; ns = not statistically significant). In BD, some dots represent >2 samples.

References

    1. World Health Organization. WHO risk assessment of human infections with avian influenza A(H7N9) virus. http://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskA... Accessed 27 Septemeber 2016.
    1. Sobhanie M, Matsuoka Y, Jegaskanda S, et al. Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against influenza A(H7N9). J Infect Dis 2016; 213:922–9. - PMC - PubMed
    1. Jackson LA, Campbell JD, Frey SE, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA 2015; 314:237–46. - PubMed
    1. Rudenko L, Isakova-Sivak I, Naykhin A, et al. H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis 2016; 16:303–10. - PMC - PubMed
    1. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, et al. What lies beneath: antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. EBioMedicine 2016; 8:277–90. - PMC - PubMed

MeSH terms